This section of is intended for U.S. healthcare professionals. Click here for the patients and families section. information for healthcare professionals.

ELAPRASE® (idursulfase) sustained improvement in selected somatic parameters.

ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older.

The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age.

Full Prescribing Information Important Safety Information


ELAPRASE is the only FDA-approved treatment for MPS II. Over 1,600 patients have been treated worldwide1.


Dosing and Administration

Recommended ELAPRASE dosing is 0.5 mg/kg of body weight, administered intravenously (IV) every week over a period of 1 to 3 hours.


Access and Product Support Services

Tools and resources for patient assistance and access to therapy.

1. Data on file; INT_RD_ELA-2-v3; Shire.